14 of the current 18 Biobanks of the German Biobank Alliance (GBA) use CentraXX
The German Biobank Alliance (GBA), which was established by the German Biobank Node (GBN) in 2017, welcomed three new partner biobanks to its network between May to September 2019: BioBank Dresden, FREEZE-Biobank Freiburg, and the Central Biobank of the CCC Tübingen-Stuttgart.
With the partner biobanks (Berliner ZebanC, Westdeutsche Biobank Essen (WBE) of the Medical Faculty at the University Hospital Essen, Comprehensive Biobank Marburg (CBBMR), Central Biobank Regensburg), which had joined the network prior to May 2019, the number of partner biobanks has expanded from 11 biobank sites and two IT centers to 18 biobank sites and two IT centers.
This means that GBA’s joint pool of samples, which scientists will be able to search for specific properties in the future, continues to grow steadily. This is made possible with the IT infrastructure.
KAIROS is extremely pleased that 14 (including DKFZ) of the 18 GBA biobanks are already using CentraXX as their central IT solution. The system will continue to be expanded and improved with the goal to achieve standardization where all users benefit from the experience and requirements of other locations.
The idea of standardizing IT solutions is an essential component of the CENTRAXX product DNA. IT development must be oriented to the often similar/comparable market requirements – not the other way around. The latest standard tools must be integrated, but must also take into account any changes in the legal framework (e.g. data protection).
KAIROS has pursued this idea throughout the entire expansion of the system into a comprehensive research portal/clinical trial management system (CTMS) that CentraXX now is.
KAIROS has just introduced the CentraXX Release 3.13.0, which now also includes an electronic Trial Master File (eTMF) module so that researchers now have the essential files of their clinical study in one location. The eTMF enables a view into the execution of the clinical study and the quality of the data collected ensuring both integrity of the clinical data and compliance with Good Clinical Practice (GCP).
With clinical studies becoming increasingly complex, the use of eTMF enables efficient scientific work.